Almost everyone carries Epstein-Barr virus. Most people pick it up in childhood or as teenagers, feel nothing or a bout of mono, and then host the virus quietly for the rest of their lives. So the fact that this near-universal passenger sits at the center of multiple sclerosis has always been hard to square. If practically all of us are infected, why do only some people develop a disease in which the immune system strips the insulation off nerve fibers in the brain and spinal cord?
A study published in Cell on January 13 offers a concrete answer to part of that puzzle. The team, led by researchers at the University of Science and Technology of China and the University of Zurich, argues that the virus does not simply sit in the background. It rewires the very B cells it infects, changing what those cells hold up for the immune system to inspect. And what they end up displaying looks alarmingly like the brain tissue that MS attacks.
The display case gets reorganized
Every cell shows off samples of the proteins inside it, loaded onto surface molecules called HLA. Immune cells patrol and read these displays. If something looks foreign, they react. People with MS very often carry a particular version of this display system, the HLA-DR15 haplotype, which is the strongest genetic risk factor known for the disease.
The researchers infected B cells with Epstein-Barr virus and then catalogued what those cells presented on their DR15 molecules. Infection changed the picture in two ways. It altered the cell's transcriptome, meaning which genes were switched on, and it reshaped the immunopeptidome, the full set of peptide fragments on display. Both viral pieces and the cell's own protein fragments shifted. The virus was, in effect, curating the display case.
The striking find came when they compared those fragments to the brain. Identical fragments of myelin basic protein, one of the main building blocks of the insulation around nerves, showed up on the infected B cells and in actual MS brain tissue. Those same fragments did not appear on ordinary uninfected B cells, and they were absent from thymic tissue, the organ where the immune system normally learns to ignore the body's own proteins. That last detail matters. If the immune system never encounters a self-fragment during its education, it never learns tolerance to it, and it can attack that fragment later without hesitation.
T cells that recognize the brain
Displaying a myelin fragment only causes trouble if immune cells respond to it. They did. The group took CD4 T cells from HLA-DR15 MS patients, both from blood and from cerebrospinal fluid, and found cells that reacted to these myelin peptides. When they grew T cell clones against the peptides, those clones went on to recognize myelin basic protein sitting in MS brain tissue itself.
So the chain closes. A common virus infects B cells. In people with the DR15 version of the display system, infection makes those cells present myelin fragments the immune system was never taught to tolerate. T cells that recognize those fragments then also recognize the real thing in the brain. Two risk factors that scientists have studied separately for decades, one infectious and one genetic, turn out to plug into the same mechanism.
What this does and does not settle
This is a mechanistic account, not a clinical trial. It explains how EBV and HLA-DR15 could work together to prime an attack on myelin, but it does not prove that this exact sequence sets off the disease in a living patient, or that interrupting it would stop MS. The experiments lean on infected cells in the lab and on tissue and immune cells from people who already have the disease. Whether the same peptides drive the earliest, symptomless stages of MS, before any diagnosis, is a separate question the data here cannot resolve.
Still, the appeal of the finding is that it converts a statistical association into something you can point at. For years the EBV-MS link rested on epidemiology, most forcefully a large study of US military recruits showing infection preceded nearly every case. Now there is a candidate molecular bridge between the virus, the genetics, and the tissue that gets damaged. If it holds up, it hints at where a therapy might intervene: the infected B cells doing the presenting, or the specific T cells that answer the call.
Comments